Loading data…
Damora Therapeutics, Inc.
Qualifying buys · 30d: eligible common-stock purchases by trade date in the 30 days through October 12, 2026, using the company snapshot.
30-day filing activity: eligible purchases from filings accepted by the SEC in the last 30 days. Acceptance dates can differ from trade dates.
Value used in Signal Score: qualifying purchases across 180 days, weighted by transaction age. The calculation and exact value are in “Why this Signal Score?” below. These totals measure different windows and should not be added together.
7 transactions · Newest trade first
Accepted in the last 30 daysInsiders bought $252.88K · 1 buyer, led by Jennifer Jarrett (CEO) with $252.88K. No qualifying insider sales.
Filing activity uses public SEC acceptance timestamps. The qualifying-buys metric above uses trade dates at the snapshot cutoff.
$227,588 of common-equity purchase value after transaction-age decay across 180 days.
1 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
Qualifying common-equity P acquisition; no disclosed plan, exercise or excluded purchase context detected.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Score is not a probability of profit or a recommendation to trade.
This reflects the filings imported so far, not a complete trading history.